Dermata Therapeutics Inc [NASDAQ: DRMA] closed the trading session at $2.48.
The stocks have a year to date performance of -72.90 percent and weekly performance of -3.88 percent. The stock has been moved at -66.29 percent over the last six months. The stock has performed 11.21 percent around the most recent 30 days and changed -50.28 percent over the most recent 3-months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If compared to the average trading volume of 1.17M shares, DRMA reached to a volume of 22511802 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Dermata Therapeutics Inc [DRMA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for DRMA shares is $10.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on DRMA stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Average True Range (ATR) for Dermata Therapeutics Inc is set at 0.62 The Price to Book ratio for the last quarter was 0.29, with the Price to Cash per share for the same quarter was set at 6.86.
DRMA stock trade performance evaluation
Dermata Therapeutics Inc [DRMA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.88. With this latest performance, DRMA shares gained by 11.21% in over the last four-week period, additionally sinking by -66.29% over the last 6 months – not to mention a drop of -86.98% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DRMA stock in for the last two-week period is set at 52.72, with the RSI for the last a single of trading hit 57.19, and the three-weeks RSI is set at 49.33 for Dermata Therapeutics Inc [DRMA]. The present Moving Average for the last 50 days of trading for this stock 2.6600, while it was recorded at 2.0300 for the last single week of trading, and 6.4300 for the last 200 days.
Dermata Therapeutics Inc [DRMA]: An insightful look at the core fundamentals
Dermata Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.78 and a Current Ratio set at 3.78.
Dermata Therapeutics Inc [DRMA]: Institutional Ownership
The top three institutional holders of DRMA stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.5034%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $178.43 billion in DRMA stocks shares; and BERKSHIRE HATHAWAY INC, currently with $135.36 billion in DRMA stock with ownership which is approximately 5.1238%.
